Scroll down to see more

Laekna Donated a Children’s Innovation Science Classroom to a School in Gansu Province


June 28, 2024 — Laekna, Inc. (2105.HK), a science-driven, clinical-stage biotechnology company, announced that the company has funded to establish a “Children’s Innovation Science Classroom” to the Taiping Town Central Primary School in Jingchuan County, Gansu Province. It helps the 322 students at the school to realize their dreams on the Children’s Day and would be able to explore and to unveil the magic of science in a brand-new, space-themed classroom. It is the second year in a row of the company to launch CSR initiatives after donating the "Cloud-Based Learning" bookshelf with 1,500 new books to Gudeng Town Middle School in Yunnan province.


In line with Laekna’s ESG strategy and social responsibility, the “Children’s Science Innovation Classroom” is a pioneering charitable initiative dedicated to promoting reading and education among rural children, with the Dandangzhe Foundation and The BayHelix Group as strategic partners of Laekna. Schools supported by this program will establish a brand-new, space-themed classroom with themes empowering scientific reading, exploration, and observation. Children can explore and unveil the magic of science in this engaging space.


“As a scientist involved in research and development activities for more than 30 years, I know that a spark from Children’s Science Innovation Classroom could ignite a dream”, said Dr. Chris Lu, Chairman and CEO of Laekna. “The classroom will inspire the future scientists to explore the world of science when they grow up. I would like to express my gratitude to the Laekna team, the Dandangzhe Foundation, and the teachers of the Taiping Town Central Primary School who have collectively made this happen. Laekna will continue to focus on science and educational charity programs in the future.”


The Journey of Laekna Children’s Innovation Science Classroom:


√ In October 2023, Laekna donated 30,000 RMB (from both of employees and the company)

√ In January 2024, the Dandangzhe Foundation selected a school as partner, signed sponsorship agreement, and delivered required materials to the school

√ In March 2024, the teachers at the Taiping Town Central Primary School decorated and painted the classroom, installed planet lights, assembled bookcases, and placed scientific pieces of equipment

√ In May 2024, conditions of the classroom was inspected and confirmed fulfilling the acceptance criteria. Hence, 322 students have their own “Science Innovation Classroom”




Contact Us




Corporate and Business Development


About Laekna

Stock Code: 2105.HK


Founded in 2016, Laekna is a science-driven, clinical-stage biotechnology company committed to bringing novel therapies to cancer, metabolic diseases and liver fibrosis patients worldwide.


As of December 31, 2023, we have initiated six clinical trials for afuresertib (LAE002), LAE001 and LAE005 for the treatment of breast cancer, prostate cancer, ovarian cancer and PD-1/ PD-L1 drug-resistant solid tumors to address the unmet medical needs. Among these six clinical trials, three are multi-regional clinical trials (MRCTs). Afuresertib is a potent AKT inhibitor that inhibits all three AKT isoforms (AKT1, AKT2 and AKT3) as well as one of the only two AKT inhibitors in or completed the pivotal-stage clinical development for anti-cancer treatment globally.


Laekna’s internal drug discovery platform has discovered 14 drug candidates. LAE102 is our internally discovered antibody against ActRIIA. We’ve obtained IND approvals from the FDA and the CDE in relation to obesity. Blocking Activin-ActRII pathway could promote muscle regeneration and decrease fat mass. Laekna team has accumulated tremendous experience and deep know-how in this specific field and is developing more drug candidates (LAE103 and LAE123) to maximize the value of targeting ActRII receptors. 


Laekna, Inc. was listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) on June 29, 2023, with the stock code 2105.HK. 

For more information, please visit:  or


Forward-Looking Statements


This press release may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on Laekna’s current beliefs, assumptions and expectations, commonly identified by words such as "would", "may", "expects", "believes", "plans", "intends", "projects" and other terms with similar meaning. Although we believe that our predictions are reasonable, future events are inherently uncertain and our actual future results or performance may be materially different from what we expect. Accordingly, you are strongly cautioned that reliance on any forward-looking statements is subject to significant known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this press release is as of the date of this press release and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement, except as required under applicable law.

RSS Feeds
If you want to know more about Laekna, please fill in the form below and sign up for emails:
  1. Name*
  2. Email*
  3. Company
  4. Occupation



Follow us on Linkedin